Artificial Intelligence in serve of Immunotherapy: prediction of quality of life, and toxicity profile


The vision of the ImmuneAI project is to reveal the patients with the greatest survival benefit by retrieving baseline clinical and biological characteristics of long-term survivors with immunotherapy. In parallel, safety and QoL profiles of the same patients will be defined, by analyzing clinical factors and patient-reported outcome measures at the time of their long-term follow-up.

For the achievement of this goal, ATC will employ Artificial Intelligence (AI) / Machine Learning (ML) techniques to identify the profile of the users, the potential benefit and the status of their QoL.

ImmuneAI is funded by ASCAPE project and aims contribute new algorithms to improve or/and train ASCAPE Open AI infrastructure to detect new types of cancer or medical conditions.

University of Brescia (Italy) and Athens Technology Center (Greece) are the partners of this project.

The project started in March 2022 and will last for 9 months.

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from - Youtube
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound